You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖(02696.HK)獲批新增24000L商業化產能,助力漢曲優®商業化全面提速
格隆匯 05-17 17:47

2022年5月17日,復宏漢霖(2696.HK)已於近日收到國家藥品監督管理局核准簽發關於漢曲優®的《藥品補充申請批准通知書》,同意漢曲優®變更生產場地、優化生產工藝及擴大製劑規模等補充申請。此次獲批標誌着松江基地(一)的24000L產能可以全部應用於漢曲優®的商業化生產,積極助力漢曲優®增效擴產,有力保障市場持續放量,也表明公司的商業化總產能擴增至48000L,成為夯實全產業鏈佈局的重要驅動力。

截至2022年3月,漢曲優®150mg已完成中國境內所有省市招標掛網和醫保準入;其60mg自2021年8月獲批上市以來,已完成中國境內23個省份的招標掛網和30個省份的醫保準入,為產品的商業化提速奠定了廣泛基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account